Wall Street analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will report $40,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 during the same quarter last year. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 14th.
According to Zacks, analysts expect that TG Therapeutics will report full year sales of $160,000.00 for the current financial year, with estimates ranging from $150,000.00 to $200,000.00. For the next year, analysts expect that the company will post sales of $170,000.00, with estimates ranging from $150,000.00 to $200,000.00. Zacks’ sales calculations are an average based on a survey of research firms that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.12. TG Therapeutics had a negative net margin of 99,001.33% and a negative return on equity of 185.20%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million.
A number of equities research analysts have issued reports on TGTX shares. ValuEngine lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 17th. LADENBURG THALM/SH SH set a $27.00 price objective on shares of TG Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 26th. Zacks Investment Research raised shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Friday, November 16th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of TG Therapeutics in a report on Monday, November 12th. Finally, Raymond James lowered shares of TG Therapeutics from a “strong-buy” rating to an “outperform” rating and cut their price objective for the company from $22.00 to $12.00 in a report on Tuesday, September 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. TG Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $18.35.
Shares of TGTX opened at $5.00 on Friday. TG Therapeutics has a 1 year low of $4.20 and a 1 year high of $17.35. The company has a market cap of $414.49 million, a price-to-earnings ratio of -2.62 and a beta of 1.72.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its position in shares of TG Therapeutics by 18.3% during the 2nd quarter. Rhumbline Advisers now owns 54,587 shares of the biopharmaceutical company’s stock valued at $718,000 after acquiring an additional 8,435 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new position in shares of TG Therapeutics during the 2nd quarter valued at approximately $146,000. RA Capital Management LLC lifted its position in TG Therapeutics by 73.1% in the second quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock worth $56,266,000 after buying an additional 1,806,452 shares during the last quarter. Bank of New York Mellon Corp lifted its position in TG Therapeutics by 11.7% in the second quarter. Bank of New York Mellon Corp now owns 276,325 shares of the biopharmaceutical company’s stock worth $3,633,000 after buying an additional 29,012 shares during the last quarter. Finally, Highland Capital Management LP lifted its position in TG Therapeutics by 1.0% in the second quarter. Highland Capital Management LP now owns 469,241 shares of the biopharmaceutical company’s stock worth $6,171,000 after buying an additional 4,850 shares during the last quarter. Hedge funds and other institutional investors own 57.30% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.